Search PubMed⌕ Search

Biomedical subjects

R Paoletti

Publications and source records attributed to R Paoletti.

At least 145 records · Page 8Linked to original sources
PubMed1985

Control of human and animal platelet aggregation by a new prostacyclin analog.

The in vitro effects of ZK 36 374, a new chemically stable prostacyclin (PGI2) analog, on platelet aggregation were studied and compared to those of PGI2. Significantly lower concentrations of ZK 36 374, versus prostacyclin, were required to inhibit collagen and epinephrine-induced aggregation in human platelet-rich plasma. In contrast, in rat and rabbit platelet rich plasma, PGI2 was more effective than ZK 36 374 in inhibiting the aggregation elicited by ADP and collagen. It is concluded that ZK 36 374 is a potent antiaggregatory compound and may be useful in the prevention of cardiovascular disorders.

Adenosine Diphosphate↗
PubMed1984

Influence of diamide on aggregation, cytoskeletal proteins, and arachidonic acid metabolism in human platelets.

Simultaneous addition of diamide (azodicarboxylic acid-bis-dimethylamide, DIA), a SH-oxidizing agent, and collagen causes a deaggregation of otherwise irreversibly aggregating platelets. Thromboxane B2 (TXB2) and 12-HE-TE formation is inhibited depending on the concentration ratio between collagen and DIA. Thus, at 0.25 mM DIA and 20 micrograms/ml collagen neither TXB2 nor 12-HETE were measurable, but a full scale reversible aggregation is induced. Deaggregation is further attained by adding DIA to collagen-induced aggregates at a time, when maximum amplitude has been achieved. Investigation of arachidonic acid (AA) metabolites under these conditions revealed no influence of DIA on AA metabolism. Therefore, AA metabolization seems to play a minor role in collagen-induced aggregation and DIA-induced deaggregation. Polymerization of certain cytoskeletal proteins of the platelets, after addition of DIA, parallels DIA-induced deaggregation. DIA inhibits endogenous AA release, probably by interaction with platelet plasma membrane. DIA seems to inhibit the release of the alpha-granula protein thrombospondin.

12-Hydroxy-5,8,10,14-eicosatetraenoic Acid↗
PubMed1984

Evaluation of enzyme activities by gas chromatography-mass spectrometry: HMGCoA reductase and cholesterol 7 alpha-hydroxylase.

Methods are described for the evaluation of HMGCoA reductase and cholesterol 7 alpha-hydroxylase activities. The methods are based on the measurement by selected-ion monitoring of mevalonate, formed from HMGCoA and of 7 alpha-hydroxycholesterol formed from cholesterol, respectively. The methods are as sensitive as those based on the use of radioisotopes but less time-consuming because quantitation is carried out on total lipid extracts. In the case of cholesterol 7 alpha-hydroxylase, the procedure does not require the use of exogenous cholesterol as the substrate, so problems related to its equilibration with endogenous microsomal cholesterol are avoided.

Animals↗
PubMed1984

The use of stable prostaglandins to investigate prostacyclin (PGI2)-binding sites and PGI2-sensitive adenylate cyclase in human platelet membranes.

Prostacyclin, (PGI2) is a potent but unstable inhibitor of platelet aggregation, probably acting through stimulation of adenylate cyclase. A stable analogue of prostacyclin with antiaggregatory properties, 5,6-dihydro-PGI2 (6 beta-PGI1), and PGE1 can compete for the binding sites labelled by 3H-PGI2 in human platelet membranes (the affinity being PGI2 greater than PGE1 greater than 6 beta-PGI1). Both 6 beta-PGI1 and PGE1, as well as PGI2, bind to two classes of binding sites. 6 beta-PGI1 and PGE1 activate adenylate cyclase to the same extent as PGI2, with a rank order of potency which parallels that observed in binding experiments. The stimulation of this enzyme is brought about by interaction of each of these prostanoids with two different classes of components. The comparison of binding and adenylate cyclase data suggests that the sites to which PGI2, 6 beta-PGI1 and PGE1 bind might be coupled to the activation of adenylate cyclase. Since 6 beta-PGI1 seems to act through the same molecular mechanisms as PGI2, because of its stability it is an useful tool to investigate the mode of action of prostacyclin in platelets.

Adenylyl Cyclases↗
PubMed1984

Dependence of arachidonic acid (AA) metabolization in human blood platelets on reduced coenzymes.

In human platelets the metabolization of AA is linked to a consumption of the reduced coenzymes NADPH and GSH which can be attributed to about 70% to the cyclooxygenase (CO) and to about 30% to the lipoxygenase (LO) pathway. In GSH depleted platelets the conversion of AA in the LO pathway to 12-HETE is strongly impaired, whereas the formation of the stable CO products from exogenous AA is not decreased, but accelerated. When platelets are deprived from GSH by oxidation to GSSG, the release of endogenous AA from phospholipids in activated platelets is inhibited.

Arachidonic Acid↗
PubMed1983

Preferential utilization of endogenous arachidonate by cyclo-oxygenase in incubations of human platelets.

Thromboxane B2 (TXB2) and 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE) formed from the endogenous and exogenous arachidonate during human platelet incubation, was evaluated by selected ion monitoring (SIM). TXB2 formed from endogenous substrate accounted for about one third of the total, whereas the great part of 12-HETE derived from exogenous arachidonate. These data indicate that under the tested conditions the pool of arachidonate that acts as substrate for cyclo-oxygenase is different from the pool that acts as substrate for lipoxygenase and that the arachidonate released from phospholipids is preferentially utilized by cyclo-oxygenase.

12-Hydroxy-5,8,10,14-eicosatetraenoic Acid↗